Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-10-14
2009-12-08
Hui, San-ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07629355
ABSTRACT:
A method is provided for treating a drug-dependent individual so as to effect withdrawal from a drug of abuse, e.g., an opiate such as heroin or oxycodone, a stimulant such as cocaine, or alcohol. The method involves substitution therapy wherein a substantially nonaddicting normorphine or norcodeine derivative is substituted for the drug of abuse. The active agent has the structure of formula (I)wherein: R is H, alkyl, or acyl; X is CH(OR′) or C═O, wherein R′ is H or acyl; α is an optional double bond, with the proviso that when α is present, then X is necessarily CH(OH), or an acid addition salt thereof, wherein preferred such agents are in a stereoisomerically pure form that corresponds to that of N-[(1R)-1-cyclopropylethyl]-normorphine (1) which melts at approximately 188° C.-189° C.
REFERENCES:
patent: 4218454 (1980-08-01), DeGraw et al.
patent: 4749706 (1988-06-01), Lawson et al.
patent: 4948803 (1990-08-01), Tyers
patent: 5366979 (1994-11-01), Lawson
Bickel et al. (1988), “A Clinical Trial of Buprenorphine: Comparison with Methadone in the Detoxification of Heroin Addicts,”Clin. Pharmacol. Ther. 43(1):72-78.
Branch et al. (1992), “Quantitation of Preproenkephalin mRNA Levels in Brain Regions from Male Fischer Rats Following Chronic Cocaine Treatment Using a Recently Developed Solution Hybridization Assay,”Molecular Brain Research14:231-238.
Crawford et al. (1995), “The Effects of the Kappa Agonist U-50,488 on Cocaine-Induced Conditioned and Unconditioned Behaviors and Fos Immunoreactivity,”Psychopharmacology120:392-399.
Daunais et al. (1993), “Cocaine Self-Administration Increases Preprodynorphin, but Not c-Fos, mRNA in Rat Striatum,”NeuroReport4(5):543-546.
Johnson et al. (1992), “A Controlled Trial of Buprenorphine Treatment for Opioid Dependence,”JAMA267(20):2750-2755.
Kuzmin et al. (2000), “Influence of Buprenorphine, Butorphanol and Nalbuphine on the Initiation of Intravenous Cocaine Self-Administration in Drug Naïve Mice,”European Neuropsychopharmacology10:447-454.
Mello et al. (1982), “Buprenorphine Effects on Human Heroin Self-Administration: An Operant Analysis,”The Journal of Pharmacology and Experimental Therapeutics223(1):30-39.
Mello et al. (1993), “Buprenorphine Treatment of Opiate and Cocaine Abuse: Clinical and Preclinical Studies,”Harvard Review Psychiatry1(3):168-183.
Mello et al. (1998), “Effects ofKappaOpioid Agonists on Cocaine- and Food-Maintained Responding by Rhesus Monkeys,”The Journal of Pharmacology and Experimental Therapeutics286(2):812-824.
Negus et al. (1997), “Effects ofKappaOpioids on Cocaine Self-Administration by Rhesus Monkeys,”The Journal of Pharmacology and Experimental Therapeutics282(1):44-55.
O'Brien et al. (1996), “Myths About the Treatment of Addiction,”The Lancet347:237-240.
Schenk et al. (1999), “U69593, A Kappa-Opioid Agonist, Decreases Cocaine Self-Administration and Decreases Cocaine-Produced Drug-Seeking,”Psychopharmacology144:339-346.
Shippenberg et al. (1996), “κ-Opioid Receptor Agonists Prevent Sensitization to the Conditioned Rewarding Effects of Cocaine,”The Journal of Pharmacology and Experimental Therapeutics276(2):545-554.
Spangler et al. (1993), “‘Binge’ Cocaine Administration Induces a Sustained Increase of Prodynorphin mRNA in Rat Caudate-Putamen,”Molecular Brain Research19:323-327.
Spangler et al. (1996), “Regulation of Kappa Opioid Receptor mRNA in the Rat Brain by ‘Binge’ Pattern Cocaine Administration and Correlation with Preprodynorphin mRNA,”Molecular Brain Research38:71-76.
Spealman et al. (1992), “Modulation of the Discriminative Stimulus Effects of Cocaine byMuandKappaOpioids,”The Journal of Pharmacology and Experimental Therapeutics261(2):607-615.
Spealman et al. (1994), “Opioid Modulation of the Discriminative Stimulus Effects of Cocaine: Comparison of μ, κ and δ Agonists in Squirrel Monkeys Discriminating Low Doses of Cocaine,”Behavioural Pharmacology5:21-31.
Suzuki et al. (1992), “The Role of Mu- and Kappa-Opioid Receptors in Cocaine-Induced Conditioned Place Preference,”Japan. J. Pharmacol. 58:435-442.
Unterwald et al. (1992), “Chronic Cocaine Alters Brain Mu Opioid Receptors,”Brain Research584:314-318.
Unterwald et al. (1994), “Repeated Cocaine Administration Upregulates κ and μ, But Not δ, Opioid Receptors,”NeuroReport5(13):1613-1616.
Wang et al. (1999), “Acute Intermittent Morphine Increases Preprodynorphin and Kappa Opioid Receptor mRNA Levels in the Rat Brain,”Molecular Brain Research66:184-187.
Yuferov et al. (1999), “Acute ‘Binge’ Cocaine Increases Mu-Opioid Receptor mRNA Levels in Areas of the Rat Mesolimbic Mesocortical Dopamine System,”Brain Research Bulletin48(1):109-112.
Aceto, et al., “Dependence Studies of New Compounds in the Rhesus Monkey, Rat and Mouse (2001),” Natl. Inst. Drug Abuse Research, Monograph, Proc. 63rdAnn. Scientific Mtg. UDHHS/NIH (2002) 182:157-210.
Hui San-ming
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Rutenberg Isaac M.
LandOfFree
Treatment of chemical dependency with substantially... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of chemical dependency with substantially..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of chemical dependency with substantially... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4141022